Melissa Alsina

Hematology | Oncology

12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 108 publications

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

Journal: Blood advances

Published: April 08, 2026

Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma.

Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma.

Journal: Cancer research

Published: March 10, 2026

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.

Journal: bioRxiv : the preprint server for biology

Published: December 19, 2025

Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma.

Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma.

Journal: Blood

Published: December 15, 2025

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

Journal: Bone marrow transplantation

Published: November 07, 2025

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Journal: Blood cancer journal

Published: November 04, 2025

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicity.

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicity.

Journal: Blood advances

Published: October 30, 2025

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity.

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity.

Journal: Blood advances

Published: October 30, 2025

Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma.

Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma.

Journal: Blood

Published: September 29, 2025

Navigating the evolving management of smoldering multiple myeloma.

Navigating the evolving management of smoldering multiple myeloma.

Journal: HemaSphere

Published: September 17, 2025

Dermatologic Adverse Effects With Elranatamab Mimicking Talquetamab.

Dermatologic Adverse Effects With Elranatamab Mimicking Talquetamab.

Journal: American journal of hematology

Published: August 05, 2025

Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease.

Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease.

Journal: Frontiers in oncology

Published: July 11, 2025

Showing 1-12 of 108

Last Updated: 09/26/2026